Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
(Hinzugefügt: 17.02.2022 um 06:52 Uhr)
Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19
(Hinzugefügt: 20.03.2021 um 18:31 Uhr)
Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series
(Hinzugefügt: 16.12.2020 um 18:53 Uhr)
Use of Intravenous Immunoglobulin Therapy Reduces Progression to Mechanical Ventilation in COVID‑19 Patients with Moderate to Severe Hypoxia
(Hinzugefügt: 09.12.2020 um 09:10 Uhr)